NorthStar Medical Radioisotopes and Chester Springs, PA-based Curadh MTR have entered a strategic collaboration agreement to develop radiopharmaceuticals for the treatment of primary and metastatic solid tumors.
Under the agreement, NorthStar will prepare and distribute patient doses of actinium-225 to Curadh for its ongoing clinical studies and, upon approval, may manufacture and supply radiopharmaceuticals for commercial use. The collaboration also dictates that NorthStar will manufacture and distribute patient doses of Curadh diagnostic and therapeutic isotopes of future interest, NorthStar said.
